Enzo Biochem Stock Operating Margin

ENZ Stock

USD 0.98 0.01 1.03%

Enzo Biochem fundamentals help investors to digest information that contributes to Enzo Biochem's financial success or failures. It also enables traders to predict the movement of Enzo Stock. The fundamental analysis module provides a way to measure Enzo Biochem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzo Biochem stock.

		Last Reported	Projected for Next Year
	Operating Profit Margin	(0.31)	(0.29)

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Enzo Biochem Company Operating Margin Analysis

Enzo Biochem's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Current Enzo Biochem Operating Margin

(0.39) %

Most of Enzo Biochem's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzo Biochem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Enzo Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Enzo Biochem is extremely important. It helps to project a fair market value of Enzo Stock properly, considering its historical fundamentals such as Operating Margin. Since Enzo Biochem's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enzo Biochem's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enzo Biochem's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Accounts Payable	Short Term Debt	Common Stock	Good Will	Property Plant Equipment	Short Term Investments	Current Deferred Revenue	Long Term Debt	Net Tangible Assets	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	-0.54	-0.15	-0.18	0.23	0.9	-0.59	0.01	0.1	0.47	0.0	0.47	0.14	-0.44	0.37	0.79	0.41	-0.35	0.42	-0.3	-0.28	-0.44	0.24
Total Stockholder Equity	0.83		-0.77	-0.33	0.17	-0.34	0.87	-0.38	0.25	-0.2	0.58	-0.09	0.24	-0.14	-0.4	0.09	0.84	0.37	-0.58	0.16	-0.1	-0.08	-0.12	0.18
Net Debt	-0.54	-0.77		0.14	-0.05	0.44	-0.8	0.1	-0.02	0.49	-0.37	0.12	0.2	0.49	0.24	0.41	-0.78	-0.39	0.4	0.35	-0.5	-0.07	-0.19	-0.25
Retained Earnings	-0.15	-0.33	0.14		-0.38	0.33	-0.01	-0.33	-0.34	-0.27	-0.9	0.49	-0.41	0.38	-0.39	-0.22	-0.2	-0.42	0.16	-0.16	0.19	0.35	0.35	-0.28
Net Receivables	-0.18	0.17	-0.05	-0.38		-0.54	-0.12	0.07	0.92	0.15	0.28	-0.31	-0.21	-0.21	0.15	-0.12	-0.16	-0.42	0.12	-0.08	0.17	0.6	0.55	-0.61
Total Liab	0.23	-0.34	0.44	0.33	-0.54		0.01	-0.35	-0.36	0.53	-0.2	0.05	0.39	0.49	-0.03	0.49	-0.12	0.01	0.43	0.45	-0.31	-0.28	-0.48	-0.01
Total Current Assets	0.9	0.87	-0.8	-0.01	-0.12	0.01		-0.54	-0.01	-0.21	0.39	-0.07	0.21	-0.01	-0.48	0.01	0.9	0.42	-0.45	0.08	0.06	-0.09	-0.12	0.2
Intangible Assets	-0.59	-0.38	0.1	-0.33	0.07	-0.35	-0.54		-0.09	-0.18	0.01	-0.11	-0.24	-0.47	0.84	-0.44	-0.42	-0.09	0.14	-0.51	0.33	0.0	0.17	0.16
Accounts Payable	0.01	0.25	-0.02	-0.34	0.92	-0.36	-0.01	-0.09		0.33	0.29	-0.32	-0.09	-0.11	0.02	0.08	-0.1	-0.49	0.18	0.12	0.03	0.58	0.43	-0.71
Short Term Debt	0.1	-0.2	0.49	-0.27	0.15	0.53	-0.21	-0.18	0.33		0.18	-0.14	0.4	0.27	0.08	0.55	-0.28	-0.12	0.65	0.5	-0.34	-0.11	-0.35	-0.15
Common Stock	0.47	0.58	-0.37	-0.9	0.28	-0.2	0.39	0.01	0.29	0.18		-0.62	0.54	-0.29	0.16	0.3	0.55	0.59	-0.34	0.27	-0.18	-0.39	-0.41	0.27
Good Will	0.0	-0.09	0.12	0.49	-0.31	0.05	-0.07	-0.11	-0.32	-0.14	-0.62		-0.36	0.18	-0.24	-0.12	-0.31	-0.32	0.06	-0.11	-0.21	0.07	0.02	0.16
Property Plant Equipment	0.47	0.24	0.2	-0.41	-0.21	0.39	0.21	-0.24	-0.09	0.4	0.54	-0.36		0.56	-0.03	0.63	0.36	0.49	-0.31	0.6	-0.61	-0.52	-0.63	0.33
Short Term Investments	0.14	-0.14	0.49	0.38	-0.21	0.49	-0.01	-0.47	-0.11	0.27	-0.29	0.18	0.56		-0.31	0.33	-0.06	-0.1	-0.12	0.34	-0.53	-0.03	-0.14	-0.06
Current Deferred Revenue	-0.44	-0.4	0.24	-0.39	0.15	-0.03	-0.48	0.84	0.02	0.08	0.16	-0.24	-0.03	-0.31		-0.18	-0.45	-0.13	0.3	-0.25	0.19	0.02	0.07	-0.01
Long Term Debt	0.37	0.09	0.41	-0.22	-0.12	0.49	0.01	-0.44	0.08	0.55	0.3	-0.12	0.63	0.33	-0.18		0.04	0.07	0.04	0.99	-0.71	-0.3	-0.6	-0.09
Net Tangible Assets	0.79	0.84	-0.78	-0.2	-0.16	-0.12	0.9	-0.42	-0.1	-0.28	0.55	-0.31	0.36	-0.06	-0.45	0.04		0.69	-0.62	0.1	0.02	-0.32	-0.26	0.39
Capital Surpluse	0.41	0.37	-0.39	-0.42	-0.42	0.01	0.42	-0.09	-0.49	-0.12	0.59	-0.32	0.49	-0.1	-0.13	0.07	0.69		-0.49	0.04	-0.12	-0.79	-0.63	0.82
Short Long Term Debt	-0.35	-0.58	0.4	0.16	0.12	0.43	-0.45	0.14	0.18	0.65	-0.34	0.06	-0.31	-0.12	0.3	0.04	-0.62	-0.49		0.0	0.29	0.31	0.16	-0.38
Long Term Debt Total	0.42	0.16	0.35	-0.16	-0.08	0.45	0.08	-0.51	0.12	0.5	0.27	-0.11	0.6	0.34	-0.25	0.99	0.1	0.04	0.0		-0.7	-0.25	-0.55	-0.13
Cash And Equivalents	-0.3	-0.1	-0.5	0.19	0.17	-0.31	0.06	0.33	0.03	-0.34	-0.18	-0.21	-0.61	-0.53	0.19	-0.71	0.02	-0.12	0.29	-0.7		0.52	0.69	-0.15
Net Invested Capital	-0.28	-0.08	-0.07	0.35	0.6	-0.28	-0.09	0.0	0.58	-0.11	-0.39	0.07	-0.52	-0.03	0.02	-0.3	-0.32	-0.79	0.31	-0.25	0.52		0.92	-0.78
Net Working Capital	-0.44	-0.12	-0.19	0.35	0.55	-0.48	-0.12	0.17	0.43	-0.35	-0.41	0.02	-0.63	-0.14	0.07	-0.6	-0.26	-0.63	0.16	-0.55	0.69	0.92		-0.6
Capital Stock	0.24	0.18	-0.25	-0.28	-0.61	-0.01	0.2	0.16	-0.71	-0.15	0.27	0.16	0.33	-0.06	-0.01	-0.09	0.39	0.82	-0.38	-0.13	-0.15	-0.78	-0.6

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict Enzo Biochem

Operating Profit Margin Over Time

Enzo Pretax Profit Margin

Pretax Profit Margin

(0.29)

At this time, Enzo Biochem's Pretax Profit Margin is fairly stable compared to the past year.

Based on the recorded statements, Enzo Biochem has an Operating Margin of -0.3875%. This is 98.9% lower than that of the Health Care Providers & Services sector and 99.39% lower than that of the Health Care industry. The operating margin for all United States stocks is 92.97% lower than that of the firm.

Enzo Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzo Biochem's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enzo Biochem could also be used in its relative valuation, which is a method of valuing Enzo Biochem by comparing valuation metrics of similar companies.

Enzo Biochem is currently under evaluation in operating margin category among its peers.

Enzo Fundamentals

	Return On Equity	-0.15
	Return On Asset	-0.0744
	Profit Margin	(0.82) %
	Operating Margin	(0.39) %
	Current Valuation	2.08 M
	Shares Outstanding	52.24 M
	Shares Owned By Insiders	23.72 %
	Shares Owned By Institutions	32.04 %
	Number Of Shares Shorted	477.48 K
	Price To Earning	26.60 X
	Price To Book	0.91 X
	Price To Sales	1.60 X
	Revenue	31.91 M
	Gross Profit	11.57 M
	EBITDA	(8.35 M)
	Net Income	(26.08 M)
	Cash And Equivalents	82.37 M
	Cash Per Share	0.44 X
	Total Debt	3.51 M
	Debt To Equity	0.38 %
	Current Ratio	2.21 X
	Book Value Per Share	1.07 X
	Cash Flow From Operations	(26.26 M)
	Short Ratio	7.55 X
	Earnings Per Share	(0.19) X
	Target Price	5.5
	Number Of Employees	125
	Beta	0.73
	Market Capitalization	50.94 M
	Total Asset	85.76 M
	Retained Earnings	(294.43 M)
	Working Capital	45.24 M
	Current Asset	91.4 M
	Current Liabilities	20.57 M
	Annual Yield	0.41 %
	Net Asset	85.76 M

About Enzo Biochem Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Enzo Biochem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzo Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzo Biochem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Enzo Stock Analysis

When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC